Recruiting PHASE2 INTERVENTIONAL 2-arm
NCT06969170
Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder
A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder
Sponsor: Diamond Therapeutics Inc.
Conditions
Generalized Anxiety Disorder (GAD)
Interventions
Placebo Psilocybin (drug)
Updated 1 time since 2025 Last updated: May 8, 2025 Started: May 6, 2025 Primary completion: Jun 1, 2026 Completion: Aug 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06969170, this PHASE2 trial focuses on Generalized Anxiety Disorder (GAD) and remains actively recruiting participants. Sponsored by Diamond Therapeutics Inc., it has been updated 1 time since 2025, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
1 version recorded Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Diamond Therapeutics Inc.
- Kingston Health Sciences Centre
- Queen's University
Data source: Queen's University
For direct contact, visit the study record on ClinicalTrials.gov .